Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Scandinavian ChemoTech AB has received approval for the CE marking

Scandinavian ChemoTech
Read the release

Scandinavian ChemoTech has been informed that we have now reached the final step of our CE certification approval for the IQwave™ and its platform, Tumour Specific Electroporation (TSE) and will receive its certificate shortly.

"It is an important milestone that now has been reached. This unique and patented technology will be able to give cancer patients and physicians a new effective weapon in the fight against resistant cancer tumours. I would like to take this opportunity to thank the organisation that has worked hard to achieve this status of our system and method." - says Mohan Frick, CEO Scandinavian ChemoTech AB

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-05-2021 10:15 CET.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.